SCHEMBL30049481

SCHEMBL30049481

CC(=O)N(C)c1ccc(S(=O)(=O)N2CCC3(CCN(CCC(C)(C)C)CC3)CC2)cn1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 6/20 0.44
▸ NPSR1 Q6W5P4 2/20 0.44
▸ GAA P10253 3/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ ALDH1A1 P00352 8/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ ATM Q13315 2/20 0.39
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ LMNA P02545 3/20 0.38
▸ HPGD P15428 2/20 0.38
▸ HTT P42858 2/20 0.38
▸ MCOLN3 Q8TDD5 1/20 0.38
▸ NLRP3 Q96P20 1/20 0.38
▸ USP5 P45974 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ TSHR P16473 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27162039 1.00 KDM4E (0.44) KDM4ENPSR1GAAMAPK1ALDH1A1
SCHEMBL30049846 0.91 KDM4E (0.42) KDM4ENPSR1GAAMAPK1ALDH1A1
SCHEMBL27162442 0.91 KDM4E (0.42) KDM4ENPSR1GAAMAPK1ALDH1A1
SCHEMBL27162739 0.90 GAA (0.41) KDM4ENPSR1GAAMAPK1ALDH1A1
SCHEMBL30049494 0.90 GAA (0.41) KDM4ENPSR1GAAMAPK1ALDH1A1
SCHEMBL27161575 0.82 CYP2D6 (0.42) KDM4EGAAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL30050945 0.82 CYP2D6 (0.42) KDM4EGAAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL30049132 0.81 CYP2D6 (0.43) KDM4EGAAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL27162687 0.81 CYP2D6 (0.43) KDM4EGAAMAPK1ALDH1A1SMN1; SMN2
SCHEMBL30050023 0.81 GAA (0.40) KDM4ENPSR1GAAMAPK1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP claimed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO claimed
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands ACONDICIONAMIENTO TARRASENSE (ES) 2024-08-01 — — US disclosed
EP-4330248-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS Acondicionamiento Tarrasense (ES) 2024-03-06 — — EP disclosed
WO-2022229405-A1 PYRIDINE-SULFONAMIDE DERIVATIVES AS SIGMA LIGANDS ACONDICIONAMIENTO TARRASENSE (ES) 2022-11-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240254115-A1 New Pyridine-Sulfonamide Derivatives as Sigma Ligands SIGMAR1, TMEM97, OPRD1 KDM4E 3959/4885NPSR1 19/4885GAA 3700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback